Celltrion and Teva announce U.S. FDA acceptance of biologics license application for proposed biosimilar to herceptin® (trastuzumab)

1st August 2017 Uncategorised 0

Teva Pharmaceutical Industries

More: Celltrion and Teva announce U.S. FDA acceptance of biologics license application for proposed biosimilar to herceptin® (trastuzumab)
Source: MDlinx